Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908602 | 0.91 | PPARA (0.48) | PPARAMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4902985 | 0.90 | PPARA (0.49) | PPARAMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4906179 | 0.85 | MEN1 (0.44) | MAPTLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4906196 | 0.84 | PPARA (0.47) | PPARAMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4904276 | 0.81 | PPARA (0.46) | PPARAALOX5 | |
| SCHEMBL4903629 | 0.79 | MAPT (0.73) | PPARAMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4905953 | 0.78 | ALDH1A1 (0.46) | MAPTLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4900796 | 0.75 | MEN1 (0.43) | MAPTSMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL5930457 | 0.74 | PPARA (0.46) | PPARALMNASMN1; SMN2ALDH1A1ALOX5 | |
| SCHEMBL4908596 | 0.72 | MAPT (0.70) | PPARAMAPTLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | PPARA 1/4885MAPT 1786/4885LMNA 319/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | PPARA 1/4885MAPT 1786/4885LMNA 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.